Ranked #1
Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)
Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)
Dr. Jack West describes recently updated results of a small randomized trial of consolidation local ablative therapy (LA... Read more
9 Dec 2018
•
9mins
Ranked #2
Is Durvalumab (Imfinzi) in Stage III NSCLC Curing Patients or Just Treating Metastatic Disease Earlier? Importance of Overall Survival and Implications for Duration of Treatment (BMIC-025)
Is Durvalumab (Imfinzi) in Stage III NSCLC Curing Patients or Just Treating Metastatic Disease Earlier? Importance of Overall Survival and Implications for Duration of Treatment (BMIC-025)
Dr. Jack West explores the importance of following the overall survival of patients on the PACIFIC trial and considers s... Read more
22 Feb 2018
•
6mins
Ranked #3
What is Positive Predictive Value of PET PSMA in Biochemical Recurrence of Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-059)
What is Positive Predictive Value of PET PSMA in Biochemical Recurrence of Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-059)
Dr. Daniel Goldstein reviews data on the positive predictive value of PET PSMA imaging in patients with biochemically re... Read more
27 Aug 2018
•
2mins
Ranked #4
IMpower133: Is there Finally a New Standard of Care for Extensive Stage SCLC? (BMIC-064)
IMpower133: Is there Finally a New Standard of Care for Extensive Stage SCLC? (BMIC-064)
Dr. Jack West reviews the IMpower133 trial that integrated atezolizumab with first line chemo for extensive stage SCLC a... Read more
6 Nov 2018
•
7mins
Most Popular Podcasts
The Joe Rogan Experience
TED Talks Daily
The Tim Ferriss Show
The Daily
Stuff You Should Know
Oprah's SuperSoul Conversations
Armchair Expert with Dax Shepard
Ranked #5
Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)
Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)
Dr. Jack West discusses the trial design of the PACIFIC trial of consolidation durvalumab (Imfinzi) after chemo/radiatio... Read more
8 Nov 2018
•
7mins
Ranked #6
Nivolumab/Ipilimumab vs. Chemo in High TMB Advanced NSCLC: Key Results from CheckMate 227 (BMIC-034)
Nivolumab/Ipilimumab vs. Chemo in High TMB Advanced NSCLC: Key Results from CheckMate 227 (BMIC-034)
Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipil... Read more
10 May 2018
•
13mins
Ranked #7
Chemo-Immunotherapy in Non-Squamous NSCLC: Has the KEYNOTE-189 Trial Defined a Clear Standard of Care? (BMIC-022)
Chemo-Immunotherapy in Non-Squamous NSCLC: Has the KEYNOTE-189 Trial Defined a Clear Standard of Care? (BMIC-022)
Dr. Jack West reviews the results and pending questions of the KEYNOTE-189 trial of chemotherapy with or without pembrol... Read more
20 Jan 2018
•
8mins
Ranked #8
Durvalumab (Imfinzi) FDA Approved for Stage III NSCLC: Should It Become Standard of Care Without Overall Survival Benefit Demonstrated? (BMIC-024)
Durvalumab (Imfinzi) FDA Approved for Stage III NSCLC: Should It Become Standard of Care Without Overall Survival Benefit Demonstrated? (BMIC-024)
Dr. Jack West reviews key results of the PACIFIC trial of the immunotherapy agent durvalumab (Imfinzi) vs. placebo in st... Read more
20 Feb 2018
•
7mins
Ranked #9
Immunotherapy with Pembrolizumab in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-055)
Immunotherapy with Pembrolizumab in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-055)
Dr. Daniel Goldstein summarizes key data in genitourinary oncology from ASCO 2018, including new results on pembrolizuma... Read more
17 Aug 2018
•
2mins
Ranked #10
Is Chemotherapy More Effective After Prior Immunotherapy? (BMIC-029)
Is Chemotherapy More Effective After Prior Immunotherapy? (BMIC-029)
Dr. Jack West presents early data suggesting that chemotherapy may be more effective after prior immunotherapy than othe... Read more
12 Apr 2018
•
5mins
Ranked #11
KEYNOTE-189: Key Summary of a Practice-Changing Trial in Advanced Non-Squamous NSCLC (BMIC-030)
KEYNOTE-189: Key Summary of a Practice-Changing Trial in Advanced Non-Squamous NSCLC (BMIC-030)
Dr. Jack West reviews the trial design, efficacy endpoints, and toxicity results of the KEYNOTE-189 trial of pembrolizum... Read more
27 Apr 2018
•
13mins
Ranked #12
New Data & Context for a PARP Inhibitor/Abiraterone Combination in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-058)
New Data & Context for a PARP Inhibitor/Abiraterone Combination in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-058)
Dr. Daniel Goldstein considers new data by Clarke & colleagues on a combination of the PARP inhibitor olaparib with ... Read more
24 Aug 2018
•
3mins
Ranked #13
My Top 5 ASCO 2018 Abstracts in Stage I-III NSCLC, Small Cell Lung Cancer, & Mesothelioma (BMIC-037)
My Top 5 ASCO 2018 Abstracts in Stage I-III NSCLC, Small Cell Lung Cancer, & Mesothelioma (BMIC-037)
Dr. Jack West reviews his top 5 abstracts in stage I-III non-small cell lung cancer, small cell lung cancer, and mesothe... Read more
23 May 2018
•
7mins
Ranked #14
My Top 5 ASCO 2018 Abstracts in Advanced NSCLC (BMIC-036)
My Top 5 ASCO 2018 Abstracts in Advanced NSCLC (BMIC-036)
Dr. Jack West reviews his top 5 abstracts in the advanced NSCLC track at ASCO 2018, explaining why each is poised to cha... Read more
21 May 2018
•
10mins
Ranked #15
T Effector Gene Signature on IMpower150: Is There a Better Biomarker than PD-L1 for Immunotherapy? (BMIC-021)
T Effector Gene Signature on IMpower150: Is There a Better Biomarker than PD-L1 for Immunotherapy? (BMIC-021)
Dr. Jack West reviews provocative biomarker results on the IMpower150 trial that tested atezolizumab with carboplatin/pa... Read more
21 Dec 2017
•
10mins
Ranked #16
Is More Better with Radium-223 for Metastatic Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-056)
Is More Better with Radium-223 for Metastatic Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-056)
Dr. Daniel Goldstein reviews data in genitourinary oncology from ASCO 2018, including a study of higher dose or prolonge... Read more
20 Aug 2018
•
1min
Ranked #17
Are Tumor Mutation Burden and Nivolumab/Ipilimumab Ready for Clinical Use? Insights from CheckMate 227 (BMIC-035)
Are Tumor Mutation Burden and Nivolumab/Ipilimumab Ready for Clinical Use? Insights from CheckMate 227 (BMIC-035)
Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipil... Read more
11 May 2018
•
9mins
Ranked #18
"Best Treatment First": Implications for front-Loading Combinations in Lung Cancer (BMIC-063)
"Best Treatment First": Implications for front-Loading Combinations in Lung Cancer (BMIC-063)
Dr. Jack West describes an emerging theme that the best outcomes for patients with lung cancer and likely other cancer a... Read more
7 Sep 2018
•
9mins
Ranked #19
Atezolizumab in First Line NSCLC: Early Clinical Results from the IMpower150 Trial (BMIC-020)
Atezolizumab in First Line NSCLC: Early Clinical Results from the IMpower150 Trial (BMIC-020)
Dr. Jack West reviews the preliminary clinical results on the IMpower150 trial that tested the value of adding the immun... Read more
18 Dec 2017
•
11mins
Ranked #20
KEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and High (≥50%) Tumor PD-L1 Expression (BMIC-031)
KEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and High (≥50%) Tumor PD-L1 Expression (BMIC-031)
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and high tumor PD-L1 on the KEYNOTE-... Read more
30 Apr 2018
•
7mins
